[quote=aossa]
[quote=Dirk R. Wijnen]
Deed GSK dat niet samen met Crucell?
In a study carried out by New York University (NYU), the efficacy of our malaria vaccine candidate was tested in NYU’s mouse malaria model. The study showed that a single administration of a prototype AdVac® vaccine protects mice upon challenge with the mouse specific parasite.
In March 2003, we entered into collaboration with the Walter Reed Army Institute of Research (WRAIR) and GlaxoSmithKline Biologicals (GSK) under a Cooperative Research and Development Agreement (CRADA). In line with this agreement, we have completed work with WRAIR and GSK to evaluate our AdVac® malaria vaccine candidate. Our vaccine candidate was tested as a stand-alone vaccine and in combination with GSK’s RTS,S malaria vaccine candidate. These studies have shown that Crucell’s AdVac® vaccine candidate efficiently primed and/or boosted malaria specific immune responses.
The GSK malaria vaccine candidate RTS,S has, as a stand-alone vaccine, been shown to confer partial protection to human volunteers in both a laboratory challenge model conducted at WRAIR and under natural challenge conditions in a field study conducted in the Gambia. Phase IIb pediatric trials conducted with RTS,S in Mozambique and reported in The Lancet medical journal in October 2004 and 2007 demonstrated further promising results, with the vaccine protecting some infants against infection and making the course of the disease less serious and life threatening in others.